TuHURA Biosciences to Present at H.C. Wainwright Conference
TuHURA Biosciences announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The company's president will present development updates.
TAMPA, Florida – TuHURA Biosciences, Inc. (NASDAQ:HURA), a company developing therapeutics to overcome resistance to cancer immunotherapy, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled for September 2026.
James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, is slated to present an update on the company's progress and development programs in immuno-oncology. TuHURA focuses on creating novel therapeutics designed to address resistance to cancer immunotherapy, a significant challenge impacting treatment efficacy.
Immuno-oncology remains a critical area of research in cancer treatment, with companies actively seeking solutions to resistance issues. TuHURA's lead candidates are currently in Phase 3 clinical trials.
The presentation at the conference will provide attendees with insights into TuHURA's clinical development pipeline and strategic direction.